Rusnano Teams Up With U.S. Fund Domain to Invest in Life Science

Print 06 March 2012
Jason Corcoran, BLOOMBERG

Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.

Rusnano, as the state-owned company is known, and Domain will invest in about 20 U.S.-based health-care technology companies involved in pharmaceuticals, biotechnology and medical devices, the Moscow-based company said today in an e-mailed statement. The partners plan to bring in co-investors, according to the statement.

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news